Investigational New Drugs: FDA Has Taken Steps to Improve the Expanded Access Program but Should Further Clarify How Adverse Events Data Are Used | U.S. GAO
Expanded Access — Innovation Pharmaceuticals Inc.
Expanded Access to Investigational Drugs - IRB - The University of Utah
Simplifying Paperwork and Increasing Patient Access to Oncology Compassionate Use Therapeutics - Medical Documentation Software, Clinical Documentation Improvement, CDI Clinical Documentation Improvement, CDI Program, Insight
Expanded Access for Unapproved Drugs and Biologics | Research
FDA Expanded Access Program: A Comprehensive Guide - BTC
U.S. FDA on Twitter: "Have you heard of “Expanded Access?” It's a potential pathway for patients with immediately life-threatening conditions to gain access to an investigational medial product. Here's how the process
Expanded Access Part 1: Introduction - YouTube
The Basics of the Individual Expanded Access Request Process: A Resource for Physicians - WCG IRB
Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs | NEJM
Why It Is Important to Develop a Good Expanded Access Policy
Do Your Patients Need Access to Investigational Drugs, Biologics, or Medical Devices Through FDA's Expanded Access Pathway? — MICHR
Right to Try fails to show 'edge' vs. Expanded Access pathway among community oncologists
The Basics of the Individual Expanded Access Request Process: A Resource for Physicians - WCG IRB
Expanded Access Policy | BeyondSpring
Right to Try Pros and Cons
Expanded Access | FDA
Exploring the Landscape for Compassionate Use | Clinigen
Expanded Access to Unapproved Drugs or Biologics - UCI Office of Research
WideTrial
Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the “Right to Try” - ScienceDirect
Individual Patient Expanded Access: Developing Principles For A Structural And Regulatory Framework | Health Affairs
Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits
Expanded Use of Investigational Drugs and Devices
Single-Patient Expanded Access: An Infographic | Expanded Access Navigator
GAO-17-564, INVESTIGATIONAL NEW DRUGS:: FDA Has Taken Steps to Improve the Expanded Access Program but Should Further Clarify Ho
Expanded Access to Investigational Drugs
